Loading...
HEPA logo

Hepion Pharmaceuticals, Inc.OTCPK:HEPA Stock Report

Market Cap US$2.4m
Share Price
n/a
1Y9.7%
7D16.2%
1D-5.6%
Portfolio Value
​
View

Hepion Pharmaceuticals, Inc.

OTCPK:HEPA Stock Report

Market Cap: US$2.4m

Hepion Pharmaceuticals (HEPA) Stock Overview

A biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. More details

HEPA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 18.4% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($2M)


HEPA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW500,428 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
500,428 investors already sharing narratives
View all narratives

Hepion Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hepion Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.079
52 Week HighUS$0.25
52 Week LowUS$0.033
Beta1.63
1 Month Change-1.25%
3 Month Change51.78%
1 Year Change9.72%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Aug 10

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Apr 25

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Oct 27

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 31

Hepion Pharma rises as company begins NASH treatment trial

Hepion Pharma (NASDAQ:HEPA) is trading 4% higher after the company said it had screened the first subject in the nonalcoholic steatohepatitis (NASH), a fatty liver disease, clinical trial testing rencofilstat in 336 subjects dosed for 12 months. The trial is being conducted at up to 121 sites in seven countries, with 85 of the sites located in the U.S. Subjects will receive either placebo or rencofilstat, administered orally once daily at doses of 75, 150, or 225 mg. The study's endpoints will evaluate improvements in both fibrosis and steatosis, with the overall study primary goal being an improvement of fibrosis score by one point without worsening of steatosis, or an improvement of steatosis without worsening of fibrosis.
Analysis Article • Jul 04

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Feb 17

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Hepion Pharmaceuticals CEO Robert Foster speaks about the global non-alcoholic steatohepatitis (NASH) endemic and the race to find a cure. How Hepion's drug Rencofilstat (CRV431) targets NASH and in a more recent study, has potential to treat liver cancer. What is in store for the biotech sector in 2022.
Seeking Alpha • Jan 21

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Hepion begins the crucial year 2022, where it will finally be determined whether CRV431 possesses anti-fibrotic/anti-inflammatory activity in NASH patients. In the case of positive data (Fibroscan, ELF score, etc.), it would not be strange to see revaluations in the share prices of x3 or even x4. On the other hand, Hepion is preparing to expand its pipeline with the start of trials in another indication of CRV431 for HCC. With a very low market capitalization of less than $100 million, the current moment offers an excellent opportunity to enter Hepion.
Seeking Alpha • Sep 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial." The main data reported by the company was the % reduction of the Pro-C3 biomarker in serum. According to my estimate, CRV431 would be the candidate drug with the greatest reducing power of Pro-C3 over time.
Analysis Article • Sep 14

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 08

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical results. The ALT reduction obtained in last phase IIa trial outperformed all competing drug candidate trials to date. I consider that Hepion presents a very good investment opportunity at current price levels, with a view to 1 or 2 years.
Analysis Article • Feb 18

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

A look at the shareholders of Hepion Pharmaceuticals, Inc. ( NASDAQ:HEPA ) can tell us which group is most powerful...

Shareholder Returns

HEPAUS PharmaceuticalsUS Market
7D16.2%-1.3%0.8%
1Y9.7%47.9%20.2%

Return vs Industry: HEPA underperformed the US Pharmaceuticals industry which returned 48.6% over the past year.

Return vs Market: HEPA underperformed the US Market which returned 18.6% over the past year.

Price Volatility

Is HEPA's price volatile compared to industry and market?
HEPA volatility
HEPA Average Weekly Movement41.6%
Pharmaceuticals Industry Average Movement9.2%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: HEPA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: HEPA's weekly volatility (42%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20132Gary Stetzhepionpharma.com

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.

Hepion Pharmaceuticals, Inc. Fundamentals Summary

How do Hepion Pharmaceuticals's earnings and revenue compare to its market cap?
HEPA fundamental statistics
Market capUS$2.44m
Earnings (TTM)-US$2.98m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.8x
P/E Ratio

Is HEPA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HEPA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$2.98m
Earnings-US$2.98m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did HEPA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 16:17
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hepion Pharmaceuticals, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Kumaraguru RajaBrookline Capital Markets
Kristen KluskaCantor Fitzgerald & Co.